drugset
drugset / Trial / NCT00411892

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

NCT00411892 ↗

Phase 3 Terminated 196 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin and pioglitazone combination therapy versus pioglitazone treatment alone.

Timeline

Start
2006-11-29
Primary completion
2008-03-18
Completion
2008-03-18

Outcome

Outcome not reported

Stopped: “See termination reason in detailed description”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pioglitazone Small molecule 45 mg —
Subject human insulin Protein / enzyme biologic — Inhaled

Indications

type 2 diabetes mellitus